Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,364 recruiting studies in this area right now.
By phase
- Not applicable9,630
- Phase 24,440
- Phase 12,682
- Phase 1/Phase 21,657
- Phase 31,400
- Phase 2/Phase 3286
- Phase 4269
Top conditions
- Breast Cancer1,208
- Prostate Cancer651
- Cancer636
- Colorectal Cancer475
- Lung Cancer420
- Ovarian Cancer341
- Multiple Myeloma327
- Pancreatic Cancer289
- Gastric Cancer285
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma260
- Solid Tumor246
- Advanced Solid Tumor229
- Head and Neck Cancer228
- Cervical Cancer223
- Endometrial Cancer212
- Advanced Solid Tumors210
- Esophageal Cancer190
Leading sponsors
- M.D. Anderson Cancer Center460
- Fudan University306
- National Cancer Institute (NCI)293
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University276
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca133
- Ruijin Hospital130
Where studies are running
- California1,397
- Texas638
- Arizona504
- Florida440
- Alabama430
- New York404
- Massachusetts341
- Maryland329
- New Jersey275
- Pennsylvania234
Recruiting studies20,364 total
- NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Birmingham, AlabamaAges 12 months–30 years - NCT03226704Enrolling by invitation
Leukapheresis to prepare CAR cell therapy
This trial collects white blood cells through a procedure called leukapheresis to help make CAR or other adoptive cell therapies. It’s for people with certain cancers who are not in remission (or are at high risk of relapse) and can meet health and lab requirements.
Bethesda, MarylandAges 3–65 - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Anchorage, AlaskaAges 18 years+ - NCT03206060RecruitingPhase 2
Lu-177 DOTATATE for hard-to-remove pheochromocytoma or paraganglioma
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
Bethesda, MarylandAges 18–100 - NCT03269578Recruiting
Share cancer or tumor samples for NIH research tracking
This trial helps the NIH collect and track your tissue or fluid samples used in cancer and tumor research. It may help researchers learn from your samples and medical information, but it is mainly about sample collection and data tracking.
Bethesda, MarylandAges 18–120 - NCT03039309Recruiting
Testing endoscopic removal for early stomach or gut growth
This study looks at endoscopic submucosal dissection, a procedure to remove early growths in the stomach or other parts of the GI tract, using the UK approach. You may benefit by having your treatment guided within a research study and closer follow-up.
PortsmouthAges 18 years+ - NCT03049072Recruiting
Registry for people treated with ion beam therapy at MedAustron
This trial is a patient registry that collects information from people treated with ion beam therapy at MedAustron. It helps researchers understand treatment patterns and outcomes and may improve care for future patients.
Wiener Neustadt, Lower AustriaAges Any age - NCT03259867RecruitingPhase 2
TACE plus immune therapy for liver or stomach cancer
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
Orange, CaliforniaAges 18–80 - NCT03093116RecruitingPhase 1/Phase 2
Repotrectinib for ALK, ROS1, or NTRK tumor gene changes
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
Duarte, CaliforniaAges 12 years+ - NCT03067051RecruitingPhase 1/Phase 2
Test of a prostate cancer light-activated treatment device
This study tests the safety and early effectiveness of the SpectraCure P18 system, which uses light-activated medicine to treat prostate cancer that has come back locally after radiation. It may help some people avoid or delay more invasive treatment, while researchers carefully watch side effects.
New York, New YorkAges 18 years+ - NCT03028246Recruiting
Safety study using focused ultrasound for certain brain tumors
This study tests whether a focused ultrasound treatment is safe for children and young adults who have a non-cancerous (benign) tumor in the center of the brain. It mainly checks safety, and it also includes monitoring before and during treatment to reduce risks like bleeding or imaging-related problems.
Washington D.C., District of ColumbiaAges 5–22 - NCT03246802Recruiting
HDR brachytherapy for prostate cancer that returned after prior radiation
This trial studies a targeted, high-dose form of radiation (HDR brachytherapy) for prostate cancer that has come back after earlier radiation treatment. It aims to treat a limited (one-area) recurrence while trying to avoid serious late side effects from repeat radiation.
Kelowna, British ColumbiaAges 45 years+ - NCT03193515Recruiting
Blood test to monitor bladder cancer returning
This trial tests a new blood test that looks for signs bladder cancer may be coming back in people with a recent history of bladder cancer. It may help by making surveillance easier, but you must still follow a scheduled bladder-check plan.
Los Angeles, CaliforniaAges 18 years+ - NCT03207854Recruiting
Donate blood and immune samples for cancer, blood, or healthy volunteers study
This study collects blood and immune-related samples from people with cancer, certain immune-related blood conditions, or healthy volunteers. It helps researchers understand immune changes and may support future diagnosis or treatments.
Los Angeles, CaliforniaAges 19 years+ - NCT03029325Recruiting
Boston lung cancer genetic study
This study looks at tissue samples from people with lung cancer to learn more about the genes and molecules that cause it. By participating, you may help doctors better understand lung cancer and improve future treatments.
Boston, MassachusettsAges 18 years+ - NCT03176836Enrolling by invitation
TP53 mutation imaging study for Li-Fraumeni syndrome
This study takes special body images (MRI) in people from families with Li-Fraumeni syndrome, especially those who carry a TP53 gene mutation. The goal is to see whether MRI can help spot problems earlier in a higher-risk group.
Toronto, OntarioAges Up to 18 years - NCT03219450RecruitingPhase 1
Personalized vaccine for early-stage, treatment-free CLL
This Phase 1 study tests a personalized cancer vaccine made from each patient’s CLL (“neoantigens”) plus a medicine called poly-ICLC to help the immune system learn to recognize the cancer. It is designed for people who have CLL but are currently not needing treatment, to see if it’s safe and may help keep the disease under control.
Boston, MassachusettsAges 18 years+ - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03145077Recruiting
MRI test to diagnose jaw bone damage after head and neck radiation
This study uses special MRI scans with contrast to better detect osteoradionecrosis (jaw bone injury) after radiation for head and neck cancer. If you qualify, the scans may help your team diagnose problems earlier and choose the right next treatment.
Houston, TexasAges 18 years+ - NCT03051464RecruitingPhase 2/Phase 3
Testing two ways to boost radiation to prevent rectal surgery
This study looks at whether two different added “boosts” of radiation can work as well for rectal cancer patients, aiming to avoid or reduce the need for rectal cancer surgery. You would receive a specific combination of radiation (including brachytherapy) and chemotherapy, and your tumor’s location and size will determine if you can take part.
Dallas, TexasAges 18–80 - NCT03096418RecruitingPhase 4
Weekly paclitaxel before surgery, using tumor tests to guide care
This trial gives weekly paclitaxel chemotherapy before breast surgery, then studies tumor “biomarkers” to see how well treatment is working. The goal is to improve how doctors predict which patients benefit and who may need different approaches.
Iowa City, IowaAges 18 years+ - NCT03295227RecruitingPhase 1
Pembrolizumab for thymus cancer that cannot be removed
This trial studies pembrolizumab, an immunotherapy medicine, in people with thymoma or thymic cancer that cannot be removed with surgery. It aims to see how well the treatment works and how safe it is, including whether your immune system can help control the cancer.
Houston, TexasAges 18 years+ - NCT03054584Recruiting
Study the genetics behind common skin moles
This study looks at why some people develop melanocytic nevi (common skin moles) by examining genetic factors. It may help researchers understand the causes of moles and could guide future skin health research.
Sacramento, CaliforniaAges 18 years+ - NCT03104491RecruitingPhase 1/Phase 2
Inotuzumab after transplant for CD22-positive leukemia
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
Westwood, KansasAges 16–75
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,364 recruiting oncology studies from the U.S. registry right now, out of 31,668 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.